Doxorubicin Hydrochloride Injectable, Liposomal
Product Images NDC 47335-050

9 FDA label images from Sun Pharmaceutical Industries, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 47335-050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-doxorubicin-structure (Spl Doxorubicin Structure)

Spl-doxorubicin-structure (Spl Doxorubicin Structure)
Chemical structure diagram of Doxorubicin Hydrochloride, showing its molecular framework with functional groups, hydroxyls, and hydrochloride component, consistent with the active ingredient in the injectable liposomal formulation.*
FDA Label Image

Spl-doxorubicin-structure1 (Spl Doxorubicin Structure1)

Spl-doxorubicin-structure1 (Spl Doxorubicin Structure1)
Chemical structure of MPEG-DSPE, showing the molecular formula with polyethoxy groups, amide linkage, phosphate group, and long hydrocarbon chains.*
FDA Label Image

Spl-doxorubicin-structure2 (Spl Doxorubicin Structure2)

Spl-doxorubicin-structure2 (Spl Doxorubicin Structure2)
Chemical structure of hydrogenated soy phosphatidylcholine (HSPC) with variable chain lengths m and n, shown as 14 or 16. The diagram illustrates the molecular formula with phosphate, choline, and fatty acid chains.*
FDA Label Image

Spl-doxorubicin-figure (Spl Doxorubicin Figure)

Spl-doxorubicin-figure (Spl Doxorubicin Figure)
Illustration depicting the structure of a pegylated liposome, showing the MPEG-DSPE coating on the surface, an aqueous core containing entrapped doxorubicin hydrochloride (HCl), and the liposomal bilayer forming the vesicle wall.*
FDA Label Image

Spl-doxorubicin-figure1 (Spl Doxorubicin Figure1)

Spl-doxorubicin-figure1 (Spl Doxorubicin Figure1)
Kaplan-Meier curve showing percent of subjects progression-free over time (months), comparing Doxorubicin plus Bortezomib versus Bortezomib alone. The graph includes censored data points and reports a p-value < 0.0001 with hazard ratio 0.55 (95% CI 0.43, 0.71). A table below lists the number of subjects at risk at various time points for both treatment groups.*
FDA Label Image

10ml-label (10ml Label)

10ml-label (10ml Label)
Label for Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) injectable liposomal formulation for intravenous use. The label includes dilution instructions, storage requirements, and a caution that it is a cytotoxic agent that must be diluted. It is supplied as a 10 mL single-dose vial by Sun Pharmaceutical Industries, Inc., with manufacturing by Sun Pharmaceutical India Ltd.*
FDA Label Image

10ml-carton-label (10ml Carton Label)

10ml-carton-label (10ml Carton Label)
Packaging label for Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) injectable liposomal formulation by Sun Pharmaceutical Industries, Inc. The label includes dosage form, strength, dilution instructions, storage conditions (refrigerate 2°C to 8°C), and manufacturer information. It specifies the product is a sterile, cytotoxic agent for intravenous infusion after dilution, presented in a 10 mL single-dose vial.*
FDA Label Image

25ml-label (25ml Label)

25ml-label (25ml Label)
Doxorubicin Hydrochloride Liposome Injection label showing 50 mg/25 mL (2 mg/mL) strength in an injectable, liposomal dosage form. The label highlights that the drug is a cytotoxic agent, must be diluted, and is for intravenous infusion only after dilution. It specifies storage instructions (refrigerate 2°C to 8°C, do not freeze) and that the vial is single-dose, 25 mL. The product is distributed by Sun Pharmaceutical Industries, Inc. and manufactured by Sun Pharmaceutical Ind. Ltd., India.*
FDA Label Image

25ml-carton-label (25ml Carton Label)

25ml-carton-label (25ml Carton Label)
The packaging label for Doxorubicin Hydrochloride Liposome Injection, 50 mg/25 mL (2 mg/mL) injectable solution by Sun Pharmaceutical Industries, Inc. The label highlights it as a sterile cytotoxic agent for intravenous infusion, with instructions that it must be diluted prior to administration. The 25 mL single-dose vial is indicated, and storage is specified between 2°C to 8°C. The label also cautions that this is a liposomal formulation and not a substitute for standard doxorubicin hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.